Frequent flyers: when another training course becomes the business plan

During a recent strategy session with a clinician entering medical aesthetics, we discussed the progress she'd made towards establishing her private practice. She'd already invested in clinical education, secured somewhere to treat patients and begun building her experience. However, her paying patient numbers remained very small, and she was still working out how to attract clients beyond her immediate personal and professional networks.

As we explored her business ambitions, it became apparent that several important commercial questions remained unanswered. She hadn't yet established a clearly defined target market, gathered sufficient evidence of local patient demand or identified what might meaningfully distinguish her practice from existing providers. Nevertheless, further clinical training was already underway, with plans to introduce additional treatments as her qualifications progressed.

Her approach was entirely understandable. She wanted to become a more knowledgeable, capable and confident practitioner, and expanding her clinical offering seemed a logical way to develop the business. In time, she hoped, a sustainable patient base would emerge around those investments.

It wasn't the first time I'd encountered this thinking. Similar themes have emerged in other conversations with clinicians, while discussions with people working in aesthetics education have raised the issue of practitioners returning repeatedly for additional courses.

It's led me to think of them as the frequent flyers of medical aesthetics: practitioners who continue accumulating clinical knowledge and qualifications, sometimes without having established a commercially sustainable practice around the skills they already possess.

The question that interests me is why further training can become the preferred response to a problem that may not be clinical at all.

The familiarity of clinical development

For many healthcare professionals entering medical aesthetics, continuing education has been a defining feature of their careers. Doctors, nurses and other clinicians operate within professional environments where acquiring knowledge, demonstrating competence and undertaking further training are both familiar and necessary.

Clinical development generally takes place within established frameworks. There are recognised qualifications, competency requirements, supervised experience and professional standards against which progress can be assessed. Although the precise requirements vary between professions and treatments, practitioners are accustomed to pursuing clearly defined educational objectives.

Business development presents a rather different challenge.

Establishing a private practice requires decisions about customer demand, competitive positioning, pricing, premises, operating costs and marketing. Unlike enrolling on a structured course, these activities rarely produce an immediate, tangible outcome. A practitioner can spend several weeks investigating a local market and still be uncertain whether the business they envisage will succeed.

More importantly, that research may reveal conclusions they weren't expecting. Perhaps the local market is already crowded with established providers offering similar treatments. Perhaps patients are more interested in a different service from the one the practitioner most wants to deliver. Or perhaps the revenue required to justify a particular investment is unrealistic given the time available alongside NHS commitments.

These are uncomfortable possibilities, particularly for someone who has already invested considerable time and money in developing a new career direction.

Against that uncertainty, another training course offers a familiar sense of progress. It provides an opportunity to develop clinical expertise, gain practical experience and work towards a recognised outcome.

There is nothing inherently wrong with that. The difficulty arises when the activity of learning is mistaken for progress towards commercial viability. A practitioner may be becoming increasingly capable clinically without getting any closer to establishing a sustainable business.

Clinical capability isn't the same as commercial demand

An important distinction needs to be made here. Appropriate clinical education, supervised experience, competence assessment and continuing professional development are essential to safe, responsible medical aesthetics practice. Level 7 qualifications can represent substantial professional development, and decisions about necessary clinical training should never be compromised in pursuit of commercial objectives.

However, there is a difference between undertaking education to establish or maintain clinical competence and purchasing additional training because you believe offering another treatment will grow your business.

The latter is also a commercial investment decision, and it deserves the same scrutiny as any other expenditure.

Being qualified to provide skin boosters, for example, doesn't establish how many patients in your local area are interested in receiving them. Learning an additional injectable technique doesn't tell you what those patients are prepared to pay, how frequently they might return or whether established competitors are already meeting demand.

Even a treatment that's growing in popularity nationally may not represent a worthwhile commercial opportunity for an individual practitioner. Local demographics, competition, patient preferences, treatment costs and available clinical capacity all influence whether it makes financial sense.

This distinction became particularly apparent during my recent consultation. When we discussed the demand for some of the treatments the practitioner was planning to introduce, she referred to their popularity on Instagram, conversations with colleagues and the fact that other clinics were already offering them.

Those observations weren't necessarily incorrect. Social media activity, competitor offerings and professional discussions can all provide useful indications of changing interests within a market. But they don't establish whether there is sufficient paying demand to support another provider.

Before recommending investment in a new treatment offering, I'd want to understand who was buying it, why they were choosing it and what they were actually paying. I'd also want to investigate the local competitive landscape, the costs involved in delivering the treatment and the number of bookings required to justify the initial investment.

For a practitioner operating one or two days a week alongside NHS employment, those calculations become particularly important. An apparently profitable treatment may look rather different once product costs, room hire, consumables, training expenditure, administration and practitioner time are considered.

Without that commercial understanding, there's a risk of developing an increasingly extensive treatment portfolio without establishing a sufficiently strong business to support it.

A treatment menu isn't a market position

There's another dimension to the frequent flyer phenomenon that I find interesting: the relationship between an expanding treatment menu and the way a practitioner positions their business.

When I ask newer practitioners to describe their ideal patients, the answers often focus on professional values and the experience they want to provide. They talk about safety, natural-looking results, medical expertise, personalised care and helping patients feel confident without dramatically changing their appearance.

These are entirely appropriate ambitions, particularly in an industry where patient trust and responsible treatment decisions matter enormously. But they're not necessarily distinctive.

Many established aesthetics clinics communicate very similar promises. Consequently, when I ask what would make a prospective patient choose one particular practitioner over another, the answer is often less clear.

This is where additional treatments can become something of a distraction. A broader menu gives a practitioner more services to advertise, but it doesn't necessarily provide patients with a more compelling reason to book.

Indeed, it can make the proposition harder to understand. A practitioner offering everything from anti-wrinkle injections and fillers to skin boosters, microneedling, hair restoration and advanced rejuvenation may have developed an impressive range of clinical capabilities. But what is the business particularly known for, who is it trying to attract, and what specific patient needs is it best placed to address?

Those questions matter because patients aren't simply comparing lists of available procedures. They're making decisions about who understands their concerns, whose expertise they trust and whether the proposed service represents value to them.

Sometimes a smaller, more clearly defined treatment offering, developed around a well-understood patient group, may provide a stronger starting point than attempting to appeal to everyone. In other circumstances, a broader service offering may be commercially appropriate. The answer depends on the evidence.

The essential point is that a longer list of treatments doesn't automatically create a stronger market position.

For practitioners considering their next elective training investment, I'd suggest examining what the qualification is expected to achieve commercially. Is there demonstrated patient demand for the additional service? Will it strengthen the existing proposition or introduce an entirely different audience? How will it affect operating costs, capacity and profitability? And could the business generate better returns by focusing on attracting patients for treatments the practitioner is already appropriately qualified and competent to deliver?

These questions aren't intended to discourage further education. They're intended to distinguish clinical development from commercial expansion, so that each investment has a clear purpose.

What happens beyond qualification?

I also think this pattern raises an interesting question for the medical aesthetics education sector.

Clinical training providers have an essential role in developing practitioners' knowledge, skills and competence. However, once those practitioners begin establishing themselves in private practice, they encounter challenges that extend well beyond clinical education.

They need to understand their market, identify prospective patients, make decisions about pricing and premises, establish workable operating arrangements and communicate their services effectively. For clinicians whose careers have largely developed within the NHS, many of these responsibilities may be entirely unfamiliar.

Some aesthetics training providers already recognise this and offer business development courses, mentoring and marketing guidance alongside their clinical programmes. That's encouraging, although I'd be interested to understand how much of the available support focuses on the commercial decisions that should inform investment, rather than moving directly into promotional activity.

Websites, social media and advertising can all play valuable roles in attracting patients. But their effectiveness depends considerably on the commercial proposition behind them. Helping a practitioner understand which patients to target, why those patients might choose them and whether their intended services are financially viable seems a sensible foundation for deciding how to market the business.

There's also an opportunity to look beyond the point of qualification.

In higher education, graduate outcomes are used to understand what happens to students after they complete their studies, including their subsequent employment and career progression. Having worked with this type of information for many years, I'm interested in how similar thinking could be applied to medical aesthetics.

For example, what proportion of practitioners are actively treating patients six or twelve months after completing their training? How many have established private practices, and how many are generating the income they originally hoped to achieve? What barriers have others encountered, and what further support might help them progress?

It would also be interesting to understand how frequently practitioners invest in additional clinical training while continuing to struggle with patient acquisition or the commercial performance of their businesses.

I wouldn't presume to know the answers, nor would I suggest that every practitioner who undertakes multiple courses is experiencing commercial difficulty. There are many legitimate reasons to continue clinical education, and not everyone entering aesthetics intends to establish a substantial private practice.

Nevertheless, a more structured understanding of post-qualification experiences could help education providers identify where additional business support might be valuable. It could also help distinguish between practitioners who need further clinical development and those who are clinically ready to progress but need assistance turning their capabilities into a viable commercial proposition.

Importantly, that support wouldn't always need to encourage immediate business expansion. In some circumstances, the most valuable outcome might be helping someone recognise that a proposed investment, treatment or practice model isn't commercially appropriate for them.

That's a useful decision in its own right.

Before booking the next course

Medical aesthetics is an industry in which continuing professional development is essential. Clinical techniques evolve, evidence develops and practitioners have a responsibility to maintain the knowledge and competence appropriate to the services they provide.

But developing clinical expertise and building a successful private practice remain two different disciplines.

A practitioner can be highly committed to education, hold respected qualifications and offer excellent patient care while still struggling to attract paying clients. When that happens, the answer isn't automatically another treatment course.

It may be that the business needs a clearer understanding of its local market, a more distinctive proposition, a different operating model or a better grasp of its treatment economics. Equally, it may need a marketing strategy that communicates more effectively with the patients it's best placed to serve.

Sometimes further clinical training will be the right investment, particularly where it's required to establish competence or where evidence supports introducing a new service. At other times, the more productive next step may be to consolidate existing capabilities and investigate why they haven't yet translated into the anticipated commercial results.

The frequent flyers I've encountered have prompted me to think more carefully about the distinction between those two situations. They haven't necessarily made poor decisions, and there's no reason to assume their further education won't eventually prove valuable. What interests me is whether the commercial reasoning behind those investments has received the same attention as the clinical development itself.

Before enrolling on another course, I'd encourage practitioners to consider one question:

Am I undertaking this qualification because my clinical development requires it, or because I'm hoping it will solve a commercial problem?

If it's the latter, perhaps the most useful next step isn't another qualification, but a closer examination of the business you're trying to build.

Strategy before spend. Always.

This article draws on anonymised practitioner conversations and informal industry observations. It does not establish how widespread repeat training behaviour is, nor does it suggest that further clinical education is unnecessary. Practitioners must obtain and maintain the training, competence and professional standards appropriate to the treatments they provide.